Drug intelligence / Profile preview

Pharyngal

Development stage: Unknown
Lead developer: Bosnalijek
Modality: Small Molecules
Administration: Oromucosal

Overview

Pharyngal is an oromucosal spray developed by Bosnalijek, indicated for the symptomatic treatment of acute sore throat, redness, and pharyngeal disorders. It combines an antiseptic, chlorhexidine, with a local anesthetic, lidocaine, to provide both antimicrobial and analgesic effects. Clinical trials have evaluated its efficacy in reducing pain, difficulty in swallowing, and swollen throat, as well as its safety profile.

Brand names: Pharyngal
Other names: Pharyngal Oromucosal Spray

Targets

SCN5A (Sodium channel protein type 5 subunit alpha)Bacterial cell membrane and associated anionic surface components

Beyond the preview

Go deeper on Pharyngal.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Pharyngal.

Explore the full profile